Fate Therapeutics appoints Matthew Abernethy to board; shareholders boost authorized shares to 350M

FATE THERAPEUTICS INC

Matthew Abernethy, CFO of Neurocrine Biosciences, appointed Class III director; Timothy P. Coughlin steps down.
Stockholders approved increase in authorized common shares from 250M to 350M, effective May 29, 2025.
Second amendment to 2022 stock plan approved, adding 7M shares to the reserve.
Dr. Shefali Agarwal and Dr. Bahram Valamehr re-elected Class III directors; E&Y ratified as auditor.
Non-binding say-on-pay passed with ~68.9M for (92.4% of votes cast); frequency set at 1 year.

item 5.02item 5.07item 5.03item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Timothy P. Coughlin

Director

FATE · FATE THERAPEUTICS INC

Effective: 2025-05-29
Successor: Matthew Abernethy
Filed: May 30, 2025 23:59 UTC

Concurrently with Mr. Abernethy’s election at the Annual Meeting, Timothy P. Coughlin’s term as a member of the Board and the Audit Committee thereof ended.

Appointed

Matthew Abernethy

Class III Director

FATE · FATE THERAPEUTICS INC

Effective: 2025-05-29
Filed: May 30, 2025 23:59 UTC

appointed Matthew Abernethy to the Board to serve as a Class III director

Source: SEC EDGAR

accession 0001193125-25-132301

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.